IDiyas

For the Inventor, By the Inventor

Marburg, Germany

Jürgen Römisch

USPTO Granted Patents = 11

Average Co-Inventor Count = 3.4

ph-index = 3

Forward Citations = 49(Granted Patents)


Company Filing History:

goldMedal10 out of 57 
 
Aventis Behring Gmbh
 patents
silverMedal1 out of 10 
 
Zlb Behring Gmbh
 patents

Years Active: 2001-2004

Loading Chart...
11 patents (USPTO):Explore Patents
1. 6835817 - Monoclonal antibody which is specific for activated coagulation factor VII, and its use (2004-12-28),
2. 6790832 - Pharmaceutical preparation for the treatment of inflammatory processes (2004-09-14),
3. 6573056 - Process for purifying factor VII and activated factor VII (2003-06-03),
4. 6528299 - Protease for activating clotting factor VII (2003-03-04),
5. 6514940 - Stabilized antithrombin III preparation (2003-02-04),
6. 6489443 - Process for the preparation of a protein solution (2002-12-03),
7. 6479245 - Monoclonal antibody which is specific for activated coagulation factor VII, and its use (2002-11-12),
8. 6450681 - Process for dissolving albumin flakes in a liquid and arrangement for carrying out the process (2002-09-17),
9. 6399572 - Pharmaceutical preparation for the treatment of inflammatory processes (2002-06-04),
10. 6248365 - Use of complement inhibitors for the preparation of a pharmaceutical for the prophylaxis and therapy of inflammatory intestinal and skin disorders as well as purpura (2001-06-19),
11. 6242239 - Process for separating HIV from a fluid (2001-06-05),

Title: The Innovative Journey of Jürgen Römisch

Introduction

Jürgen Römisch, an accomplished inventor located in Marburg, Germany, has made significant contributions to the field of biomedical research and drug development. With a total of 11 patents to his name, Römisch's work showcases his dedication to advancing healthcare through innovative solutions.

Latest Patents

Among his latest patents are notable developments in the realm of monoclonal antibodies. One such patent describes a monoclonal antibody specifically designed to bind only activated coagulation factor VII (factor VIIa), while avoiding binding to complexed forms with antithrombin III. This antibody, isolated from the hybridoma cell line DSM ACC 2332, offers valuable applications in detecting factor VIIa in various body fluids, blood coagulation preparations, and human tissues. Additionally, Römisch has developed a pharmaceutical preparation aimed at treating inflammatory processes characterized by increased cytokine and tissue factor distribution in the body, which includes Antithrombin III as its active ingredient.

Career Highlights

Jürgen Römisch's professional journey includes significant tenures at notable companies in the pharmaceutical and biotechnology sectors. He has worked with Aventis Behring GmbH and ZLB Behring GmbH, contributing to advancements in therapeutic solutions and research. His work not only highlights his inventive prowess but also showcases his ability to contribute to the development of life-saving medications.

Collaborations

Throughout his career, Römisch has collaborated with esteemed coworkers such as Annette Feussner and Gerhard Dickneite. These partnerships have played a crucial role in driving innovation and advancing research projects, leading to successful patent filings and the development of new therapeutic options.

Conclusion

Jürgen Römisch stands as a testament to the power of innovation in medicine. His dedication to developing effective therapeutic solutions and his contributions to the field through his patents underscore the importance of creativity and collaboration in advancing healthcare. As he continues to build on his legacy, Römisch remains a notable figure in the world of biomedical inventions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…